Off-Label Promotion Seems On Track: Judge Supportive Of Amarin, Skeptical Of FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral arguments didn't go particularly well for the agency in its effort to limit what Amarin can tell doctors about unapproved use of Vascepa.